Highest-materiality recent filing
LB Pharma Q2 net loss $51.6M, cash $327.8M, NOVA-2 readout accelerated to H1 2027
Q2 2026 net loss $51.6M vs $4.9M; R&D expenses $44.1M vs $2.4M.
LB Pharmaceuticals raises $150M in private placement for pipeline expansion
Gross proceeds of ~$150M from sale of 3,577,560 shares at $34.94 and pre-funded warrants for 715,513 shares.
LB Pharma accelerates Phase 3 NOVA-2 topline to H1 2027; cash runway into Q2 2029
Topline results from Phase 3 NOVA-2 trial of LB-102 in schizophrenia now expected in first half of 2027, ahead of prior guidance.
LB Pharma Q1 net loss $19.1M; cash $365.6M; Phase 3 schizophrenia trial launched
Net loss of $19.1M in Q1 2026 vs $5.3M in Q1 2025; R&D expenses rose $11.2M to $14.6M.
LB Pharmaceuticals reports Q4 net loss $11.5M; cash $295.2M; advances LB-102 into Phase 3
Positive Phase 2 (NOVA-1) results for LB-102 in acute schizophrenia met primary endpoint; Phase 3 NOVA-2 initiated March 2026 with data expected H2 2027.
LB Pharmaceuticals raises $100M in private placement; Phase 2 MDD trial for LB-102 starts early 2027
Gross proceeds ~$100M from sale of 3.31M shares and 1.42M pre-funded warrants at $21.17/share.
LB Pharmaceuticals appoints Kaya Pai Panandiker as Chief Commercial Officer
Effective Nov 10, 2025; Panandiker previously CCO at Neumora Therapeutics.
LB Pharmaceuticals Reports Q3 2025 Results and Provides Trial Updates
Net loss narrowed to $3.6M in Q3 2025 from $14.2M in Q3 2024.
On June 8, 2026, she resigned from her position as Chief Medical Officer of the Company effective June 15, 2026 (the " Separation Date ").
Max materiality 0.85 · Median 0.60 · Most common event other_material